QXOH-
Levobupivacaine (LB) is a fixed-dose combination of 35-mM
QXOH and 10-mM LB. It was developed for perioperative
analgesia because of its long-acting
analgesic effect. The purpose of this study was to evaluate the potential toxicity of
QXOH-LB in beagle dogs in accordance with the Guidance on the repeated-dose toxicity published by the China Food and Drug Administration. Groups of five male and five female beagle dogs received
normal saline,
QXOH-LB (2, 4, and 8 mg/kg, calculated as
QXOH),
QXOH (2, 4, and 8 mg/kg), or LB (2 mg/kg, equals the concentration of LB in 8-mg/kg
QXOH-LB group) at the volume of 1 mL/kg once per day for 14 days through
subcutaneous injection. No mortality was observed. Dogs in the control group as well as animals treated with 2-mg/kg
QXOH or
QXOH-LB exhibited normal behaviors. Clinical signs of toxicity in dogs treated with 4 and 8 mg/kg of
QXOH or
QXOH-LB included decreased activity,
unsteady gait, jerks,
tremors, vocalization,
emesis,
ataxia, lateral/sternal recumbency, deep/rapid respiration, and gasping. Additionally, neurological function was found to be affected by
QXOH and
QXOH-LB at the doses of 4 and 8 mg/kg. All clinical signs were recovered within 24 h. The no-observed-adverse-effect level of
QXOH and
QXOH-LB was considered to be 2 mg/kg. Toxicokinetic data showed that exposure to
QXOH and LB increased as
QXOH-LB doses were increased from 4 to 8 mg/kg. There was no evidence of drug accumulation or any effect of gender.